Lundbeck's experimental drug cuts migraine days in mid-stage trial

Lundbeck said its experimental migraine drug bocunebart cut monthly migraine days in a mid-stage study, supporting further development of the treatment. The result is a positive clinical proof point for the company’s pipeline, though it remains early-stage and does not yet indicate regulatory approval or commercialization.

Analysis

Lundbeck said its experimental migraine drug bocunebart cut monthly migraine days in a mid-stage study, supporting further development of the treatment. The result is a positive clinical proof point for the company’s pipeline, though it remains early-stage and does not yet indicate regulatory approval or commercialization.